Loading…
Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.
Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.
Relies on a single brand franchise, Naoxintong, sold through hospitals and drugstores under national reimbursement listing. It markets heavily to doctors and pharmacy chains, so selling expenses are the main cost. Founder-controlled.
Moat: narrow (brand). Well-known branded TCM formula for stroke/cardiovascular care with established physician trust.
Headquarters: Shandong, China · Employees: 7,237
Size Shandong Buchang Pharmaceuticals (603858.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.31B, the 1107th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.10 on 6 Nov 2026.
Performance Over six months the shares fell 7.2%, against -13.4% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median -0.9%); the operating margin is 9.8% (peer median 8.6%).
Valuation It trades at 1.5× enterprise value to sales against a peer median of 4.0× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥11.4B | CN¥11.8B | CN¥10.9B | CN¥13.1B | CN¥14.8B |
| Revenue growth | — | +8% | -17% | -11% | — |
| Gross profit | CN¥7.25B | CN¥7.21B | CN¥6.17B | CN¥8.57B | CN¥10.2B |
| EBITDA | n/a | CN¥1.69B | CN¥1.30B | CN¥1.65B | CN¥2.30B |
| Net income | CN¥282M | CN¥361M | -CN¥554M | CN¥319M | -CN¥1.53B |
| Free cash flow | CN¥784M | CN¥1.05B | CN¥753M | -CN¥694M | CN¥2.24B |
| Capital expenditure | CN¥196M | CN¥123M | CN¥197M | CN¥530M | CN¥543M |
| Total debt | CN¥4.11B | CN¥3.86B | CN¥3.76B | CN¥3.41B | CN¥3.39B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals 603858.SS | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% |
| Tasly Pharmaceutical 600535.SS | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $4.02B | -6% | +32% | 21% | 3.1× | -3.2% |
| Jiangsu Kanion Pharmaceutical 600557.SS | $1.05B | -6% | +8% | 7% | 1.5× | 3.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603858.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.4% | -0.6% | 8th highest of 21 |
| 6-month return | -7.2% | -13.4% | 10th highest of 21 |
| Distance from 52-week high | -18.2% | -27.1% | 6th highest of 21 |
| Revenue growth (TTM) | +4.2% | -0.9% | 6th highest of 19 |
| Operating margin | 9.8% | 8.6% | 8th highest of 18 |
| EV / Sales | 1.5× | 4.0× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -2.2% | 2.4% | 4th least demanding of 14 |
| Growth delivered (Del g) | -5.8% | +6.4% | lowest of 14 |
| Hurdle (Req g minus delivered) | +3.6 pp | -3.1 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | +3.8 pp | -2.5 pp | 5th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% | -5.8% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% | +341.1% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% | +0.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 1.3× | 13.1% | +0.8% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 8.9× | 3.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 3.4× | 6.1% | +6.4% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 17.5× | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | 30.2× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | 15.5× | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 2.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 2.4× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 56.6× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 0.9× | -2.9% | +8.2% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 2.4× | 49.9% | +19.3% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 7.7× | 24.4% | -2.4% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 3.6× | -0.2% | +2.9% |